



Patents

From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications.

Intellectual Property

The following articles are protected by the following United States patents for Moderna Inc.

Spikevax™ (mRNA-1273 COVID-19 VACCINE)

US 11,524,023

[US 11,485,972](#)

[US 10,898,574](#)

[US 10,703,789](#)

[US 10,702,600](#)

[US 10,577,403](#)

[US 10,442,756](#)

[US 10,266,485](#)

[US 10,064,959](#)

[US 9,868,692](#)

In addition, Moderna Inc. owns additional patents in the United States and foreign jurisdictions.

Investors

Investors overview [!\[\]\(e3275251d0893157c3584e20c81dc3ba_img.jpg\)](#)

Newsroom

News and media

Media kit

Patents

Patents

Media Center

All media

Blogs

Videos

Podcasts

Partnerships

Strategic collaborators

Careers

Life at Moderna

People behind the science

Awards

Join our team 

Innovation Incubator

New Venture Labs



[Terms of use](#)

[Privacy statement](#)

[Contact Moderna](#)

[Sitemap](#)

© 2023 Moderna, Inc.